Loading...
The anti–SARS-CoV-2 monoclonal antibodies casirivimab and imdevimab are authorized in combination by the FDA (and recommended by the Infectious Diseases Society of America and National Institutes of Health COVID-19 Treatment Guidelines Panels) for treatment of non-hospitalized patients with mild-to-moderate COVID-19 who are at high risk for progression. A manufacturer-sponsored, phase 3 clinical trial of this cocktail (REGEN-COV; formerly known as REGN-COV2) informed the authorization and recommendations.
This analysis included about 4000 outpatients who received either 1200-mg or 2400-mg intravenous casirivimab and imdevimab or placebo. The investigators evaluated participants who were SARS-CoV-2–positive by PCR at baseline and had at least…